What is the expected growth rate for the medical business in the short term, and what are the factors that will impact this growth
ly because of a contact-free economy that is beginning to emerge; virtual conferences, virtual investor discussions, how you order your Christmas gifts, how you order grocery. All of this is really an example of how this contact-free economy and digital acceleration that is really driving the growth of semiconductor. So you want to think about our electronic business not so much with the mobile revolution how you thought about our business then -- in the last decade where mobile revolution was really the biggest growth driver for us. But going forward, you want to think about our electronic business more in terms of digital acceleration. So that would mean, two to three times GDP kind of growth over the long cycle.
And on infrastructure, it is still slow. We are continuing to get orders, we're continuing to work on those things, but it is not at the same rate as one you would expect. So 5G in our mind is still an emerging opportunity.
Jeffrey D. Hammond -- KeyBanc Capital Markets -- Analyst
Okay. And then medical, you characterized as stable. I guess, I think this business is historically kind of a high-single-digit, low-double-digit grower, and maybe I'm just assuming stable means a little bit of growth. But I'm just trying to understand how you think the growth rate shapes up for medical and kind of these puts and takes around elective surgeries, maybe coming back as we get vaccine distribution versus kind of comps from PPE equipment, etc.?
Sundaram Nagarajan -- President and Chief Executive Officer
Yeah. So I think that's a great question, Jeff. In terms of our medical business, there are really two parts to the medical business that sort of allow us to have flat-to-low single-digits, but you got to remember the context. Context really is, our med device customers are down 10%, 15%. So that's the context. And so why are we doing better than in that context, it's really because we have a fluid component business which is really serving the biopharma end markets as well as fluid components for COVID-type therapies, right?
So what you're finding is our fluid component business is doing incredibly well, which is muting some of the declines we're seeing in our interventional component business, which is directly correlated to the selective surgeries and elective surgeries. So big picture, if you think about our elective-selective surgery kind of related component business, it's down a little bit, down a bit.
In the long-term, all of the drivers; aging population, single-use component, outsourcing our med device component, all of those are intact. As things normalize, we will return to mid-to-high single-digit kind of growth of this business, and that's our expectation. And right now in this transition, if you think about elective surgeries, in July, they were down about 75%. They were 75% up pre-COVID levels, elective surgeries were. And our expectation was they were going to improve, but they have not. So as you know, as these elective surgeries improve, what you're going to find is that we will benefit from it and we will return to our mid-single-digits, high-single-digits kind of growth in the medical business. So let me stop there. If you have any follow-up, I certainly will be happy to.
Jeffrey D. Hammond -- KeyBanc Capital Markets -- Analyst
No, that's great. Just maybe last one. I understand the uncertainty. Just give us a sense of what you need to see or I don't know if it's just a couple more quarters before you kind of flip to a more full year kind of outlook? Thanks.
Sundaram Nagarajan -- President and Chief Executive Officer
Yeah. Joe, you want to take that?
Joseph P. Kelley -- Executive Vice President and Chief Financial Officer
Yeah. Our hope is that our visibility will improve or I should say our confidence as it relates to the volatile time that we're in with the pandemic here in Q1 and Q2. And so our hope is that by the time we have our Investor Day that Naga referenced, we will resume annual guidance at that time.
Jeffrey D. Hammond -- KeyBanc Capital Markets -- Analyst
Okay. Thanks so much everyone.
Sund
ly because of a contact-free economy that is beginning to emerge; virtual conferences, virtual investor discussions, how you order your Christmas gifts, how you order grocery. All of this is really an example of how this contact-free economy and digital acceleration that is really driving the growth of semiconductor. So you want to think about our electronic business not so much with the mobile revolution how you thought about our business then -- in the last decade where mobile revolution was really the biggest growth driver for us. But going forward, you want to think about our electronic business more in terms of digital acceleration. So that would mean, two to three times GDP kind of growth over the long cycle.
And on infrastructure, it is still slow. We are continuing to get orders, we're continuing to work on those things, but it is not at the same rate as one you would expect. So 5G in our mind is still an emerging opportunity.
Jeffrey D. Hammond -- KeyBanc Capital Markets -- Analyst
Okay. And then medical, you characterized as stable. I guess, I think this business is historically kind of a high-single-digit, low-double-digit grower, and maybe I'm just assuming stable means a little bit of growth. But I'm just trying to understand how you think the growth rate shapes up for medical and kind of these puts and takes around elective surgeries, maybe coming back as we get vaccine distribution versus kind of comps from PPE equipment, etc.?
Sundaram Nagarajan -- President and Chief Executive Officer
Yeah. So I think that's a great question, Jeff. In terms of our medical business, there are really two parts to the medical business that sort of allow us to have flat-to-low single-digits, but you got to remember the context. Context really is, our med device customers are down 10%, 15%. So that's the context. And so why are we doing better than in that context, it's really because we have a fluid component business which is really serving the biopharma end markets as well as fluid components for COVID-type therapies, right?
So what you're finding is our fluid component business is doing incredibly well, which is muting some of the declines we're seeing in our interventional component business, which is directly correlated to the selective surgeries and elective surgeries. So big picture, if you think about our elective-selective surgery kind of related component business, it's down a little bit, down a bit.
 In the long-term, all of the drivers; aging population, single-use component, outsourcing our med device component, all of those are intact. As things normalize, we will return to mid-to-high single-digit kind of growth of this business, and that's our expectation. And right now in this transition, if you think about elective surgeries, in July, they were down about 75%. They were 75% up pre-COVID levels, elective surgeries were. And our expectation was they were going to improve, but they have not. So as you know, as these elective surgeries improve, what you're going to find is that we will benefit from it and we will return to our mid-single-digits, high-single-digits kind of growth in the medical business. So let me stop there. If you have any follow-up, I certainly will be happy to.
Jeffrey D. Hammond -- KeyBanc Capital Markets -- Analyst
No, that's great. Just maybe last one. I understand the uncertainty. Just give us a sense of what you need to see or I don't know if it's just a couple more quarters before you kind of flip to a more full year kind of outlook? Thanks.
Sundaram Nagarajan -- President and Chief Executive Officer
Yeah. Joe, you want to take that?
Joseph P. Kelley -- Executive Vice President and Chief Financial Officer
Yeah. Our hope is that our visibility will improve or I should say our confidence as it relates to the volatile time that we're in with the pandemic here in Q1 and Q2. And so our hope is that by the time we have our Investor Day that Naga referenced, we will resume annual guidance at that time.
Jeffrey D. Hammond -- KeyBanc Capital Markets -- Analyst
Okay. Thanks so much everyone.
Sund